Deborah Telman - Gilead Sciences Gen Affairs
| GILD Stock | MXN 2,288 22.70 1.00% |
Insider
Deborah Telman is Gen Affairs of Gilead Sciences
| Age | 58 |
| Phone | 650 574 3000 |
| Web | https://www.gilead.com |
Deborah Telman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Deborah Telman against Gilead Sciences stock is an integral part of due diligence when investing in Gilead Sciences. Deborah Telman insider activity provides valuable insight into whether Gilead Sciences is net buyers or sellers over its current business cycle. Note, Gilead Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Gilead Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Deborah Telman over a month ago Disposition of 187 shares by Deborah Telman of Gilead Sciences at 93.07 subject to Rule 16b-3 |
Gilead Sciences Management Efficiency
The company has return on total asset (ROA) of 0.1045 % which means that it generated a profit of $0.1045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.216 %, meaning that it generated $0.216 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| L Bengoa | Grupo Carso SAB | N/A | |
| Jennifer Smoter | UnitedHealth Group Incorporated | N/A | |
| Srinivas Tallapragada | Salesforce, | 48 | |
| Gregory Karawan | Genworth Financial | 58 | |
| Teri Little | Applied Materials | 58 | |
| Rupert Bondy | UnitedHealth Group Incorporated | 61 | |
| Brian Thompson | UnitedHealth Group Incorporated | N/A | |
| Joseph Pon | Applied Materials | N/A | |
| Jose Celorio | Grupo Sports World | 39 | |
| Engineer Garcia | Grupo Carso SAB | 62 | |
| Melissa Hagerman | Genworth Financial | 55 | |
| Jerome Upton | Genworth Financial | 59 | |
| Michael Sullivan | Applied Materials | N/A | |
| Sir Witty | UnitedHealth Group Incorporated | 58 | |
| Brice Hill | Applied Materials | 56 | |
| CFA IV | Genworth Financial | 57 | |
| Kazutoshi Kuwahara | Genworth Financial | N/A | |
| Rohit Gupta | Genworth Financial | 48 | |
| Gavin Patterson | Salesforce, | N/A | |
| Fabian Bifaretti | Grupo Sports World | 59 | |
| John II | Genworth Financial | N/A | |
Management Performance
Gilead Sciences Leadership Team
Elected by the shareholders, the Gilead Sciences' board of directors comprises two types of representatives: Gilead Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gilead. The board's role is to monitor Gilead Sciences' management team and ensure that shareholders' interests are well served. Gilead Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gilead Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel ODay, Chairman of the Board, CEO | ||
| Johanna Mercier, Chief Commercial Officer | ||
| Deborah Telman, Gen Affairs | ||
| Jyoti Mehra, Ex HR | ||
| Jacquie CFA, VP Relations | ||
| Diane Wilfong, Corp VP | ||
| Andrew Dickinson, Executive Vice President - Corporate Development and Strategy | ||
| Michael Quigley, VP Biology | ||
| Linda Higgins, VP Innovation |
Gilead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Gilead Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.22 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.17 % | |||
| Operating Margin | 0.40 % | |||
| Current Valuation | 2.55 T | |||
| Shares Outstanding | 1.25 B | |||
| Shares Owned By Institutions | 84.16 % | |||
| Price To Earning | 282.94 X | |||
| Price To Book | 5.19 X | |||
| Price To Sales | 79.06 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gilead Stock Analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.